Cargando…

MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance

The Raf/MEK/ERK and PI3K/Akt pathways are prominent effectors of oncogenic Ras. These pathways negatively regulate each other, but the mechanism involved is incompletely understood. We now identify MEK1 as an essential regulator of lipid/protein phosphatase PTEN, through which it controls phosphatid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zmajkovicova, Katarina, Jesenberger, Veronika, Catalanotti, Federica, Baumgartner, Christian, Reyes, Gloria, Baccarini, Manuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cell Press 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625979/ https://www.ncbi.nlm.nih.gov/pubmed/23453810 http://dx.doi.org/10.1016/j.molcel.2013.01.037

Ejemplares similares

Salmonella-Induced Caspase-2 Activation in Macrophages: A Novel Mechanism in Pathogen-Mediated Apoptosis
por: Jesenberger, Veronika, et al.
Publicado: (2000)

MEK1 is required for the development of NRAS-driven leukemia
por: Nowacka, Joanna D., et al.
Publicado: (2016)

Protective Role of Raf-1 in Salmonella-Induced Macrophage Apoptosis
por: Jesenberger, Veronika, et al.
Publicado: (2001)

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma
por: Yang, H, et al.
Publicado: (2017)

“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
por: Cseh, Botond, et al.
Publicado: (2014)

Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development
por: Galabova-Kovacs, Gergana, et al.
Publicado: (2008)

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
por: Yajima, Ichiro, et al.
Publicado: (2012)

PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors
por: Smith, Amanda M., et al.
Publicado: (2019)

Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma
por: Gehringer, Franziska, et al.
Publicado: (2019)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors
por: Smith, Amanda M., et al.
Publicado: (2020)

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
por: Steelman, Linda S., et al.
Publicado: (2011)

PTEN suppresses tumorigenesis by directly dephosphorylating Akt
por: Bu, Lang, et al.
Publicado: (2021)

circPTEN suppresses colorectal cancer progression through regulating PTEN/AKT pathway
por: Li, Chen, et al.
Publicado: (2021)

Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis
por: Procaccia, Shiri, et al.
Publicado: (2017)

Counteracting the activation of pAkt by inhibition of MEK/Erk inhibition reduces actin disruption-mediated apoptosis in PTEN-null PC3M prostate cancer cell lines
por: AHN, YONG-TAE, et al.
Publicado: (2013)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
por: Byron, Sara A, et al.
Publicado: (2012)

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
por: Milella, Michele, et al.
Publicado: (2017)

MEK1/2 activity modulates TREM2 cell surface recruitment
por: Schapansky, Jason, et al.
Publicado: (2020)

Pten is necessary for the quiescence and maintenance of adult muscle stem cells
por: Yue, Feng, et al.
Publicado: (2017)

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
por: Stewart, A., et al.
Publicado: (2015)

Overexpression of LRIG1 regulates PTEN via MAPK/MEK signaling pathway in esophageal squamous cell carcinoma
por: Jiang, Xiaofang, et al.
Publicado: (2016)

Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs: Effect of Akt/mTOR inhibition on PTEN expression
por: Wan, Linyan, et al.
Publicado: (2022)

LAPTM5 mediates immature B cell apoptosis and B cell tolerance by regulating the WWP2-PTEN-AKT pathway
por: Wang, Ying, et al.
Publicado: (2022)

An ERK-Dependent Feedback Mechanism Prevents Hematopoietic Stem Cell Exhaustion
por: Baumgartner, Christian, et al.
Publicado: (2018)

The effect Akt2 deletion on tumor development in Pten(+/−) mice
por: Xu, P-Z, et al.
Publicado: (2012)

Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma
por: Ewald, Florian, et al.
Publicado: (2015)

PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells
por: Phadngam, Suratchanee, et al.
Publicado: (2016)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
por: Heinzerling, Lucie, et al.
Publicado: (2019)

PTEN regulation of the proliferation and differentiation of auditory progenitors through the PTEN/PI3K/Akt-signaling pathway in mice
por: Sun, Chen, et al.
Publicado: (2014)

Activation of PAR2 by tissue factor induces the release of the PTEN from MAGI proteins and regulates PTEN and Akt activities
por: Mohammad, Mohammad A., et al.
Publicado: (2020)

Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway
por: Ramakrishnan, Vijay, et al.
Publicado: (2012)

The MEK2-binding tumor suppressor hDlg is recruited by E-cadherin to the midbody ring
por: Gaudet, Suzanne, et al.
Publicado: (2011)

Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway
por: De Velasco, Marco A., et al.
Publicado: (2012)

Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity
por: Cao, Juxiang, et al.
Publicado: (2009)

Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN()()
por: Nakakido, Makoto, et al.
Publicado: (2015)

PTEN and AKT1 Variations in Childhood T-Cell Acute Lymphoblastic Leukemia
por: Küçükcankurt, Fulya, et al.
Publicado: (2020)

Columbamine-Mediated PTEN/AKT Signal Pathway Regulates the Progression of Glioma
por: Niu, Hai-Tao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hrmesblq303jsj6o7tgfie6c2f